Product sales rose nearly 23 percent during the year, but this was offset by a 34 percent dip in revenue from an R&D collaboration with Quest Diagnostics.
The French molecular diagnostics company said almost 95 percent of its revenue during the quarter came from its R&D collaboration with Quest Diagnostics.
The company and the hospital will conduct a clinical study into the detection and prevention of the disease.
Under the arrangement, the partners will use Genomic Vision's molecular combing technology to identify genetic variations underlying different diseases.
A 56 percent increase in revenues from the French molecular diagnostic firm's collaboration with Quest Diagnostics drove up overall revenue growth.
The firm said the drop in revenues was due to a lack of milestone payments from Quest Diagnostics, which accounted for half of all revenues in the prior-year period.
Through its agreement with Quest Diagnostics, the company plans to launch a BRCA1/2 test, followed by tests for Lynch syndrome and HPV.
The alliance is developing new optical DNA mapping technologies for diagnostic applications.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.